Impact of Mézières Rehabilitative Method in Patients with Parkinson’s Disease: A Randomized Controlled Trial

Table 2

Quality of life: comparison between groups at T1 (end of treatment) and T2 (follow-up) for SF-36 and subscales.

SF-36	Group B; (); T1		Group A; (); T1			Group B; (); T2		Group A; (); T2
	Median	IQR	Median	IQR		Median	IQR	Median	IQR
PF	75.00	35.00	75.00	15.00	.40	85.00	45.00	85.00	25.00	.90
PR	100.00	50.00	100.00	50.00	.50	100.00	45.00	100.00	37.50	.60
BD	61.00	31.00	62.00	30.00	.20	61.00	50.00	72.00	43.50	.20
GH	47.00	25.00	47.00	24.80	.60	45.00	33.00	42.00	37.50	.90
VT	50.00	15.00	57.50	15.00	.10	50.00	23.00	55.00	27.50	.50
SF	75.00	25.00	87.30	25.00	.60	87.50	23.00	87.50	25.00	.75
RE	66.70	34.00	100.00	33.80	.20	100.00	50.00	100.00	33.40	.40
MH	64.00	28.00	70.00	28.00	.30	60.00	28.00	76.00	22.00	.10

value by Mann–Whitney test. Group A: Mézières treatment group; Group B: control group. IQR: interquartile range; SF-36: Short Form 36 Health Survey; PF: physical functioning; PR: physical role functioning; BD: bodily pain; GH: general health perceptions; VT: vitality; SF: social role functioning; RE: emotional role functioning; MH: mental health.